CUPR
Cuprina Holdings (Cayman) Limited Class A Ordinary SharesCUPR
CUPR
About: Cuprina Holdings (Cayman) Ltd is a biomedical and biotechnology company that is dedicated to the development and commercialization of products for the management of chronic wounds, as well as operating in the health and beauty sector. It manufactured and distributed a line of medical grade sterile blowfly larvae bio-dressing products marketed under the MEDIFLY brand name, or the MEDIFLY products. The MEDIFLY products are used as a biological debridement tool for chronic wounds, in a procedure known as Maggot Debridement Therapy, or MDT, which is an effective alternative to surgical debridement.
Employees: 14
0
Funds holding %
of 7,430 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
1.77% more ownership
Funds ownership: 0% [Q1] → 1.77% (+1.77%) [Q2]
Research analyst outlook
We haven’t received any recent analyst ratings for CUPR.
Financial journalist opinion
Negative
Benzinga
2 weeks ago
Are You Holding These 6 Potential Pump-And-Dump Stocks? The Bear Cave Sees These As The Next Targets
Last week, The Bear Cave investigative financial newsletter warned of widespread pump-and-dump scams coordinated via WhatsApp groups and fake investment firms that target U.S.-listed Chinese stocks.
Neutral
GlobeNewsWire
1 month ago
Cuprina Appoints Dr. Ronald Sherman, Leader in Maggot Debridement Therapy, as Medical and Scientific Director; Secures FDA-approved Medical Maggot License for U.S. Market
SINGAPORE, July 21, 2025 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited (Nasdaq: CUPR) (“CUPR” or “the Company”), a biomedical and biotechnology company dedicated to the development and commercialization of products for the management of chronic wounds and infertility, as well as cosmeceuticals for the health and beauty sector, today announced that Dr. Ronald A. Sherman, a leading innovator in the use of medical maggots to treat chronic wounds, has agreed to join the Company as Medical and Scientific Director in September 2025.
Neutral
GlobeNewsWire
1 month ago
Cuprina Provides Update on Research Studies with Three Leading Education Institutes
SINGAPORE, June 30, 2025 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited (Nasdaq: CUPR) (“Cuprina” or “the Company”), a biomedical and biotechnology company dedicated to the development and commercialization of products for the management of chronic wounds and infertility, as well as cosmeceuticals for the health and beauty sector, today provided an update on progress achieved in relation to three studies carried out with institutes of higher learning. The studies, each one year in length, were aimed at helping Cuprina and these institutes jointly produce collagen peptide molecules derived from American bullfrog skin.
Neutral
GlobeNewsWire
2 months ago
Cuprina Completes Lab Able to Supply MEDIFLY Chronic Wound Therapy Across MENA Region, Secures Exclusive License to Market Medicinal Leeches in GCC Countries
SINGAPORE, June 04, 2025 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited (Nasdaq: CUPR) (“CUPR” or “the Company”), a biomedical and biotechnology company dedicated to the development and commercialization of products for the management of chronic wounds and infertility, as well as cosmeceuticals for the health and beauty sector, today announced that its indirect 49%-owned associate, Cuprina MENA Co. Ltd, had completed the set-up of a laboratory, located in Saudi Arabia, equipped to manufacture the company's MEDIFLY maggot debridement therapy for the treatment of chronic wounds and to supply the therapy across the Middle East and North Africa (“MENA”) region. Cuprina MENA is now working towards obtaining the regulatory approvals, including the Saudi Food and Drug Authority license and ISO 13485 certification, required in order to sell the therapy in the MENA region.
Neutral
GlobeNewsWire
3 months ago
Cuprina Holdings Announces Closing of Underwriter's Over-Allotment Option in Connection with Initial Public Offering
SINGAPORE, May 08, 2025 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited (Nasdaq: CUPR) (“Cuprina” or “the Company”), a biomedical and biotechnology company dedicated to the development and commercialization of products for the management of chronic wounds and infertility, as well as cosmeceuticals for the health and beauty sector, today announced that it closed the sale of an additional 450,000 Class A ordinary shares of the Company, pursuant to the full exercise of the underwriter's over-allotment option granted in connection with the Company's initial public offering (“IPO”, together with such over-allotment closing, the “Offering”), at the IPO price of $4.00 per share, less underwriting discounts. As a result, the Company has raised aggregate gross proceeds of $13,800,000, including the previously announced IPO gross proceeds of $12,000,000, prior to deducting underwriting discounts and commissions and estimated offering expenses payable by the Company.
Neutral
GlobeNewsWire
3 months ago
Cuprina Holdings Announces Completion, Receipt of Certification and License, for IVF Media Production Facility Built in Collaboration with Ferti-Craft Pte Ltd.
SINGAPORE, May 05, 2025 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited (Nasdaq: CUPR) (“Cuprina” or “the Company”), a biomedical and biotechnology company dedicated to the development and commercialization of products for the management of chronic wounds and infertility, as well as cosmeceuticals for the health and beauty sector, today announced it had, on April 6, 2025, completed construction of, and obtained ISO 13485 certification and a dealer license for, an operational in-vitro fertilization (“IVF”) media production facility in Singapore.
Neutral
GlobeNewsWire
3 months ago
Cuprina Holdings (Cayman) Limited Announces Closing of Initial Public Offering
SINGAPORE, May 05, 2025 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited (Nasdaq: CUPR) (“CUPR” or “the Company”), a biomedical and biotechnology company dedicated to the development and commercialization of products for the management of chronic wounds as well as cosmeceuticals for the health and beauty sector, today announced the closing of its previously announced initial public offering of an aggregate 3,000,000 Class A Ordinary Shares (“the Offering”) at a price of $4.00 per share (“the Offering Price”) to the public, for a total of $12.0 million of gross proceeds to the Company, before deducting underwriting discounts and offering expenses.
Neutral
GlobeNewsWire
3 months ago
Cuprina Holdings (Cayman) Limited Announces Pricing of $12 million Initial Public Offering
SINGAPORE, May 05, 2025 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited (“CUPR” or “the Company”), a biomedical and biotechnology company dedicated to the development and commercialization of products for the management of chronic wounds as well as cosmeceuticals for the health and beauty sector, today announced the pricing of its firm commitment initial public offering of an aggregate 3,000,000 shares of its Class A Ordinary Shares (“the Offering”), all of which are being offered by CUPR at a public offering price of $4.00 per share (“the Offering Price”).
Neutral
GlobeNewsWire
3 months ago
Cuprina Holdings Announces Completion, Receipt of Certification and License, for IVF Media Production Facility Built in Collaboration with Ferti-Craft Pte Ltd.
SINGAPORE, May 05, 2025 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited (Nasdaq: CUPR) (“Cuprina” or “the Company”), a biomedical and biotechnology company dedicated to the development and commercialization of products for the management of chronic wounds and infertility, as well as cosmeceuticals for the health and beauty sector, today announced it had, on April 6, 2025, completed construction of, and obtained ISO 13485 certification and a dealer license for, an operational in-vitro fertilization (“IVF”) media production facility in Singapore.
Positive
Seeking Alpha
4 months ago
U.S. IPO Weekly Recap: Flurry Of Small Issuers List, Despite Heightened Market Volatility
Seven IPOs and one SPAC debuted this week. One IPO and three SPACs submitted initial filings. Two sizable deals are set to lead the IPO calendar in the coming week.
Charts implemented using Lightweight Charts™